Table 2.
Use of antihypertensive medications during follow-up in the SPRINT participants with CKD
| Medication Usage | Intensive Treatment, n=1330 | Standard Treatment, n=1316 |
|---|---|---|
| No. of medications | ||
| Mean no. of medications (SD) | 2.90 (1.24) | 2.02 (1.23) |
| Zero medications, no. (%) | 25 (1.9) | 123 (9.3) |
| One medication, no. (%) | 124 (9.3) | 359 (27.3) |
| Two medications, no. (%) | 376 (28.3) | 399 (30.3) |
| Three medications, no. (%) | 398 (29.9) | 278 (21.1) |
| Four or more medications, no. (%) | 407 (30.6) | 157 (11.9) |
| RAS blockers, no. (%) | 953 (71.7) | 750 (57.0) |
| Angiotensin-converting enzyme inhibitor | 471 (35.4) | 396 (30.1) |
| Angiotensin receptor blocker | 482 (36.2) | 355 (27.0) |
| Direct renin inhibitor | 0 | 0 |
| Diuretics, no. (%) | 895 (67.3) | 613 (46.6) |
| Thiazide type | 622 (46.8) | 396 (30.1) |
| Loop diuretics | 249 (18.7) | 200 (15.2) |
| Aldosterone receptor antagonists | 113 (8.5) | 60 (4.6) |
| Other potassium-sparing diuretics | 38 (2.9) | 39 (3.0) |
| α-1 Blockers, no. (%) | 172 (12.9) | 88 (6.7) |
| Central α-2 agonists or other central-acting drugs, no. (%) | 51 (3.8) | 22 (1.7) |
| Calcium channel blockers, no. (%) | 810 (60.9) | 491 (37.3) |
| Dihydropyridines | 753 (56.6) | 428 (32.5) |
| Nondihydropyridines | 64 (4.8) | 66 (5.0) |
| Direct vasodilators, no. (%) | 153 (11.5) | 55 (4.2) |
| β-Blockers, no. (%) | 694 (52.2) | 555 (42.2) |
Listed are the mean numbers of medications taken by participants as well as the numbers of participants taking various numbers of medications and specific medication classes at the study visit immediately before termination of the SBP intervention. RAS, renin-angiotensin system.